ORGS - Orgenesis Inc Stock Price, Fair Value and News

0.50USD0.00 (0.00%)Market Closed

Market Summary

USD0.500.00

Market Closed

0.00%

ORGS Stock Price

View Fullscreen

ORGS RSI Chart

ORGS Valuation

Market Cap

15.9M

Price/Earnings (Trailing)

-0.29

Price/Sales (Trailing)

30.07

EV/EBITDA

2.76

Price/Free Cashflow

-0.94

ORGS Price/Sales (Trailing)

ORGS Profitability

Operating Margin

-1080.19%

EBT Margin

1886.79%

Return on Equity

263.84%

Return on Assets

-380.44%

Free Cashflow Yield

-106.24%

ORGS Fundamentals

ORGS Revenue

Revenue (TTM)

530.0K

Rev. Growth (Yr)

-98.62%

Rev. Growth (Qtr)

-98.42%

ORGS Earnings

Earnings (TTM)

-55.4M

Earnings Growth (Yr)

-739.44%

Earnings Growth (Qtr)

-171.81%

Breaking Down ORGS Revenue

Last 30 days

-41.2%

Last 90 days

61.3%

Trailing 12 Months

-56.1%

How does ORGS drawdown profile look like?

ORGS Financial Health

Current Ratio

0.25

Debt/Equity

-0.9

Debt/Cashflow

-0.78

ORGS Investor Care

Shares Dilution (1Y)

24.78%

Diluted EPS (TTM)

2.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	35.9M	35.6M	27.8M	530.0K
2022	35.6M	35.8M	35.9M	36.0M
2021	31.5M	32.8M	34.2M	35.5M
2020	32.5M	31.7M	30.9M	30.1M
2019	23.5M	26.0M	28.4M	33.3M
2018	13.5M	15.2M	16.9M	18.7M
2017	7.9M	8.6M	9.4M	10.1M
2016	3.7M	4.3M	5.0M	6.4M
2015	0	1.8M	2.4M	3.0M
2011	0	0	596.8K	1.2M
2010	0	0	0	2.5K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Orgenesis Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	miller victor	acquired	12,500	0.5	25,000	chief financial officer
Feb 01, 2024	safier jacob	bought	3,331	0.3299	10,100	-
Jan 31, 2024	safier jacob	bought	1,726	0.3452	5,000	-
Jan 30, 2024	safier jacob	bought	8,245	0.3298	25,000	-
Jan 26, 2024	safier jacob	bought	8,000	0.32	25,000	-
Jan 25, 2024	safier jacob	bought	7,920	0.3168	25,000	-
Jan 22, 2024	safier jacob	bought	2,900	0.29	10,000	-
Jan 18, 2024	safier jacob	bought	3,309	0.3309	10,000	-
Jan 11, 2024	safier jacob	bought	659	0.3297	2,000	-
Jan 10, 2024	safier jacob	bought	3,690	0.369	10,000	-

Which funds bought or sold ORGS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	unchanged	-	6,000	15,000	-%
Apr 18, 2024	CHAPIN DAVIS, INC.	unchanged	-	6,426	16,440	0.01%
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	1,000	1,000	-%
Apr 16, 2024	TSFG, LLC	sold off	-100	-1,000	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-110,329	463,050	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-4,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	6,007	6,007	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-9,477	44,392	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	added	18.00	-6.00	118	-%
Feb 14, 2024	Walleye Capital LLC	sold off	-100	-17,030	-	-%

Are Funds Buying or Selling ORGS?

Are funds buying ORGS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ORGS

No. of Funds

Unveiling Orgenesis Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	safier jacob	15.6%	4,988,000	SC 13G/A
Sep 07, 2023	new dimensions trading	15.4%	4,734,860	SC 13G/A
Jan 19, 2023	newtech investment holdings, llc	6.0%	6	SC 13G
Nov 21, 2022	new dimensions trading	5.36%	1,370,000	SC 13G
Feb 14, 2022	bergen asset management, llc	2.9%	710,115	SC 13G/A
Feb 16, 2021	sphera funds management ltd.	0.00%	10	SC 13G/A
Oct 22, 2020	bergen asset management, llc	5.6%	1,350,526	SC 13G
Aug 14, 2020	knoll capital management, lp	5.9%	1,316,364	SC 13G
May 26, 2020	phoenix holdings ltd.	4.90%	1,078,502	SC 13G/A
Jan 29, 2020	phoenix holdings ltd.	7.06%	1,140,910	SC 13G

Recent SEC filings of Orgenesis Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	S-3	S-3
Apr 19, 2024	8-K	Current Report
Apr 15, 2024	10-K	Annual Report
Apr 15, 2024	10-Q/A	Quarterly Report
Apr 15, 2024	10-Q/A	Quarterly Report
Apr 15, 2024	10-Q/A	Quarterly Report
Apr 15, 2024	8-K	Current Report
Apr 11, 2024	8-K	Current Report
Apr 02, 2024	4	Insider Trading
Apr 01, 2024	NT 10-K	NT 10-K

Peers (Alternatives to Orgenesis Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Orgenesis Inc News

Latest updates

Orgenesis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q3	2019Q2
Revenue	-100.0%	-	110,000	6,975,000	7,044,000	13,624,000	7,988,000	7,201,000	7,212,000	7,052,000	6,892,000	8,676,000	10,545,000	9,389,000	9,477,500	9,566,000	27,121,000	21,369,500	15,618,000	4,185,000	4,529,000	4,873,000
Cost Of Revenue	16.5%	162,000	139,000	3,232,000	2,722,000	24,306,000	983,000	1,063,000	714,000	-	13,461,500	10,007,000	9,727,000	770,000	-	-	243,000	170,000	6,572,500	6,364,000	-	1,007,000
Gross Profit	-47351.7%	-13,761,000	-29,000	3,743,000	4,322,000	11,251,000	7,005,000	6,138,000	6,498,000	-	-	-	-	-	-	-	-	-	-	2,757,000	-	2,822,000
S&GA Expenses	2029.6%	26,513,000	1,245,000	3,337,000	4,039,000	6,831,000	3,104,000	2,803,000	2,851,000	-	2,749,000	6,092,000	2,901,000	2,968,000	7,802,000	4,042,000	3,611,000	3,518,000	3,139,000	2,412,000	-	2,789,000
R&D Expenses	272.2%	3,007,000	808,000	3,527,000	3,281,000	3,761,000	3,683,000	7,838,000	6,651,000	-	11,168,000	10,007,000	9,727,000	5,357,000	47,199,000	6,951,000	24,963,000	4,873,000	3,477,000	2,508,000	-	2,073,000
EBITDA Margin	3614.2%	23.29	-0.66	-0.19	-0.24	-0.26	-0.37	-0.62	-0.54	-0.44	-0.44	-4.44	-4.03	-3.26	-3.16	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	785,000	-	391,000	67,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-135.8%	-141,000	394,000	91,000	129,000	172,000	25,000	11,000	1,000	-	43,000	67,000	-	-2,000	-1,662,000	18,000	-12,000	47,000	166,000	44,000	-	19,000
Earnings Before Taxes	344.4%	29,961,000	-12,259,000	-3,570,000	-4,132,000	-1,100,000	-1,383,000	-5,481,000	-3,996,000	-	-4,975,000	-10,084,000	-2,725,000	-167,000	-140,491,000	9,584,000	27,109,000	7,062,000	5,193,000	4,229,000	-	4,892,000
EBT Margin	2586.3%	18.87	-0.76	-0.29	-0.34	-0.33	-0.44	-0.69	-0.61	-0.50	-0.51	-4.49	-4.08	-3.31	-3.21	-	-	-	-	-	-	-
Net Income	-171.8%	-34,392,000	-12,653,000	-4,127,000	-4,189,000	-4,097,000	-1,356,000	-5,427,000	-4,009,000	-	-5,016,000	-10,159,000	-2,659,000	-219,000	48,258,000	2,427,000	20,406,000	-69,981,000	6,060,000	4,549,000	-	5,201,000
Net Income Margin	-11465.2%	-104	-0.90	-0.39	-0.42	-0.41	-0.44	-0.69	-0.61	-0.51	-0.51	1.03	1.46	2.25	0.04	-	-	-	-	-	-	-
Free Cashflow	66.1%	-502,000	-1,481,000	-6,465,000	-8,485,000	-16,182,000	-7,576,000	-9,864,000	-3,694,000	-6,970,000	-6,970,000	-10,173,000	-12,512,000	-5,077,000	-45,460,000	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-67.9%	14,552	45,299	54,767	93,267	90,928	70,690	62,799	58,538	59,841	65,204	75,558	82,110	77,684	110,752	119,196	127,209	92,495	79,599	84,555	84,770	73,876
Current Assets	-53.6%	4,076	8,776	9,295	49,450	46,318	31,856	25,458	24,010	25,758	36,341	47,848	54,713	50,077	94,983	104,312	112,930	78,348	20,773	27,092	23,932	28,058
Cash Equivalents	1421.8%	837	55.00	180	2,674	5,311	3,015	2,303	1,123	5,473	14,917	28,431	41,841	44,923	88,758	97,487	107,069	107	10,707	16,655	14,762	14,999
Inventory	0%	34.00	34.00	34.00	128	120	95.00	107	113	118	133	173	200	185	153	176	126	136	1,859	2,221	1,992	1,660
Net PPE	-1.9%	1,475	1,503	1,249	21,808	22,834	16,526	14,388	11,104	10,271	5,706	4,100	3,469	3,073	2,560	2,295	2,405	2,305	17,742	14,295	12,783	12,458
Goodwill	-67.3%	1,211	3,703	3,703	8,069	8,187	7,764	8,174	8,329	8,403	8,414	8,599	8,602	8,745	4,763	4,658	4,592	4,812	14,489	15,066	15,002	4,942
Liabilities	8.0%	35,535	32,902	30,802	33,959	31,654	40,440	30,956	23,681	21,210	21,943	24,058	27,358	24,956	23,944	30,807	37,546	55,462	44,363	43,488	39,136	22,902
Current Liabilities	14.7%	16,407	14,302	12,711	13,938	15,910	34,168	16,245	15,253	15,365	13,566	18,156	18,930	16,285	12,355	19,758	25,910	42,434	24,363	23,064	21,752	17,161
Short Term Borrowings	51.2%	650	430	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	3.1%	18,967	18,394	17,834	17,290	13,343	5,162	13,943	7,544	4,854	7,277	4,656	7,082	7,200	10,503	10,262	10,779	12,143	8,465	8,319	1,242	1,214
LT Debt, Current	-100.0%	-	2,540	-	-	4,504	-	5,568	3,357	5,885	4,382	6,719	4,327	3,974	393	393	383	416	397	389	382	382
LT Debt, Non Current	-100.0%	-	18,394	17,834	17,290	13,343	5,162	13,943	7,544	4,854	7,277	4,656	7,082	7,200	10,503	10,262	10,779	12,143	8,465	8,319	1,242	1,214
Shareholder's Equity	-269.3%	-20,983	12,397	23,965	29,003	27,561	30,250	31,843	34,857	38,631	43,261	51,500	54,752	52,728	86,808	88,389	89,663	6,078	11,097	16,754	21,401	26,750
Retained Earnings	-24.2%	-176,622	-142,230	-129,577	-125,000	-121,261	-117,164	-115,808	-110,381	-106,372	-101,356	-91,197	-88,538	-88,319	-36,707	-34,280	-13,874	-89,429	-83,224	-78,675	-73,474	-65,163
Additional Paid-In Capital	0.7%	156,837	155,819	154,743	154,691	150,355	149,465	146,919	146,290	145,916	145,338	143,197	142,449	140,397	128,647	128,076	109,197	94,691	94,439	94,415	94,049	90,597
Shares Outstanding	4.6%	31,877	30,467	28,467	27,862	25,546	25,404	24,711	24,601	24,281	24,278	24,366	24,193	24,168	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	1,336	1,510	38.00	90.00	155	143	145	137	203	149	148	155	149	601	631	639	639	645
Float	-	-	-	35,034	-	-	-	54,810	-	-	-	109,567	-	-	-	105,399	-	-	-	56,803	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	57.5%	-502	-1,181	-5,954	-7,200	-10,737	-4,957	-6,414	-2,792	-2,464	-8,355	-11,500	-4,547	-45,227	-9,985	-9,141	-13,693	-2,706	-2,346	-3,657	-4,511	-
Share Based Compensation	0%	76.00	76.00	152	159	288	194	232	268	564	293	324	564	579	571	831	866	631	462	891	1,073	-
Cashflow From Investing	92.6%	-62.00	-843	-1,495	-1,307	-6,675	-2,595	-3,250	-1,613	-5,740	-5,082	-1,023	-539	1,745	1,093	-273	103,045	-6,509	-3,322	-1,584	-2,363	-
Cashflow From Financing	-23.3%	1,225	1,597	4,886	5,910	19,483	9,189	10,905	1.00	-1,095	-4.00	-905	1,898	-269	-9.00	-198	6,357	10,416	-114	7,194	6,602	-
Buy Backs	-	-	-	-	-	-	-	-	-	107	-	899	10.00	-	-	-	-	-	-	-	-	-

ORGS Income Statement

2023-12-31

Consolidated Statements of Comprehensive Loss (Income) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Total revenues	$ 530	$ 36,025
Cost of revenues	6,255	5,133
Gross (loss) profit	(5,725)	30,892
Cost of development services and research and development expenses	10,623	21,933
Amortization of intangible assets	721	911
Selling, general and administrative expenses included credit losses of $24,367 for the year ended December 31, 2023	35,134	15,589
Share in net loss of associated companies	734	1,508
Impairment of investment	699
Impairment of intangible assets		1,061
Operating loss	53,636	10,110
Loss from deconsolidation of Octomera (see Note 3)	5,343
Other income, net	(4)	(173)
Credit loss on convertible loan receivable	2,688
Loss from extinguishment in connection with convertible loan	283	52
Financial expenses, net	2,499	1,971
Loss before income taxes	64,445	11,960
Tax expense	473	209
Net loss	64,918	12,169
Net (loss) income attributable to non-controlling interests	(9,557)	2,720
Net loss attributable to Orgenesis Inc.	$ 55,361	$ 14,889
Loss per share:
Basic	$ 1.91	$ 0.59
Diluted	$ 1.91	$ 0.59
Weighted average number of shares used in computation of Basic and Diluted loss per share:
Basic	29,007,869	25,096,284
Diluted	29,007,869	25,096,284
Comprehensive loss:
Net loss	$ 64,918	$ 12,169
Other Comprehensive loss – Translation adjustment	49	477
Release of translation adjustment due to deconsolidation of Octomera	(384)
Comprehensive loss	64,583	12,646
Comprehensive (loss) income attributed to non-controlling interests	(9,557)	2,720
Comprehensive loss attributed to Orgenesis Inc.	55,026	15,366
Nonrelated Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Total revenues	530	34,741
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Total revenues		$ 1,284

ORGS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 837	$ 5,311
Restricted cash	642	1,058
Accounts receivable, net of credit losses of $0	88	36,183
Prepaid expenses and other receivables	2,017	958
Convertible loan		2,688
Inventory	34	120
Total current assets	4,076	46,318
NON CURRENT ASSETS:
Deposits	38	331
Equity investees	8	39
Loans to associates		96
Property, plants and equipment, net	1,475	22,834
Intangible assets, net	7,375	9,694
Operating lease right-of-use assets	351	2,304
Goodwill	1,211	8,187
Deferred tax		103
Other assets	18	1,022
Total non-current assets	10,476	44,610
TOTAL ASSETS	14,552	90,928
CURRENT LIABILITIES:
Accrued expenses and other payables	2,218	2,648
Income tax payable	740	289
Employees and related payables	1,079	1,860
Advance payments on account of grant	2,180	1,578
Short-term loans	650
Current maturities of finance leases	18	60
Current maturities of operating leases	216	542
Short-term and current maturities of convertible loans	2,670	4,504
TOTAL CURRENT LIABILITIES	16,407	15,910
LONG-TERM LIABILITIES:
Non-current operating leases	96	1,728
Convertible loans	18,967	13,343
Retirement benefits obligation		163
Finance leases	4	95
Other long-term liabilities	61	415
TOTAL LONG-TERM LIABILITIES	19,128	15,744
TOTAL LIABILITIES	35,535	31,654
REDEEMABLE NON-CONTROLLING INTEREST		30,203
EQUITY (CAPITAL DEFICIENCY):
Common stock of $0.0001 par value: Authorized at December 31, 2023 and December 31, 2022: 145,833,334 shares; Issued at December 31, 2023 and December 31, 2022: 32,163,630 and 25,832,322 shares, respectively; Outstanding at December 31, 2023 and December 31, 2022: 31,877,063 and 25,545,755 shares, respectively.	3	3
Additional paid-in capital	156,837	150,355
Accumulated other comprehensive income (loss)	65	(270)
Treasury stock 286,567 shares as of December 31, 2023 and December 31, 2022	(1,266)	(1,266)
Accumulated deficit	(176,622)	(121,261)
Equity attributable to Orgenesis Inc.	(20,983)	27,561
Non-controlling interests		1,510
TOTAL EQUITY (CAPITAL DEFICIENCY)	(20,983)	29,071
TOTAL LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND EQUITY (CAPITAL DEFICIENCY)	14,552	90,928
Related Party [Member]
CURRENT ASSETS:
Accounts receivable, net of credit losses of $0
Receivables from related parties	458
CURRENT LIABILITIES:
Accounts payable	133
Other payable related parties	52
Nonrelated Party [Member]
CURRENT LIABILITIES:
Accounts payable	$ 6,451	$ 4,429

About Orgenesis Inc

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

CEO	Ms. Vered Caplan M.Sc.
WEBSITE	orgenesis.com
INDUSTRY	Biotechnology
EMPLOYEES	167

Orgenesis Inc Frequently Asked Questions

What is the ticker symbol for Orgenesis Inc? What does ORGS stand for in stocks?

ORGS is the stock ticker symbol of Orgenesis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Orgenesis Inc (ORGS)?

As of Fri Apr 26 2024, market cap of Orgenesis Inc is 15.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORGS stock?

You can check ORGS's fair value in chart for subscribers.

What is the fair value of ORGS stock?

You can check ORGS's fair value in chart for subscribers. The fair value of Orgenesis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Orgenesis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ORGS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Orgenesis Inc a good stock to buy?

The fair value guage provides a quick view whether ORGS is over valued or under valued. Whether Orgenesis Inc is cheap or expensive depends on the assumptions which impact Orgenesis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORGS.

What is Orgenesis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, ORGS's PE ratio (Price to Earnings) is -0.29 and Price to Sales (PS) ratio is 30.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORGS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Orgenesis Inc's stock?

In the past 10 years, Orgenesis Inc has provided -0.073 (multiply by 100 for percentage) rate of return.